Clostridium Butyricum Miyairi 588
Sarcomatoid Renal Cell Carcinoma
City of Hope Medical Centerother_biologicalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Sarcomatoid Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab City of Hope Medical Center | Phase 3 | BB |
Sorafenib National Cancer Institute (NCI) | Phase 2 | BB |
Ipilimumab City of Hope Medical Center | Phase 3 | BB |
Cabozantinib City of Hope Medical Center | Phase 3 | BB |
Pazopanib Mayo Clinic | Phase 2 | B |
View all 16 →
Same molecule, other indications
Clostridium Butyricum Miyairi 588 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →